NAD+

NAD+ and Ageing: What Is Actually Established

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Tissue NAD+ levels decline with age across multiple species, and Covarrubias and colleagues reported in Nature Metabolism in 2020 that senescent cells drive this decline by increasing CD38 activity. Whether restoring NAD+ reverses age-related changes is a separate question and much less settled.

Key facts

Decline observed
Across tissues and species
Mechanism reported
Senescent cells increase CD38
Key paper
Covarrubias, Nat Metab 2020 (PMID 33199924)
Review
Covarrubias, Nat Rev Mol Cell Biol 2021
Restoration benefit
Not established in humans
Human outcome data
Limited

The observation

NAD+ levels fall with age in multiple tissues and multiple species. This is reasonably well replicated and is the empirical foundation the whole field rests on. It is a description of what happens, and on its own it says nothing about whether the decline causes anything.

The mechanism

Covarrubias and colleagues reported in 2020 that senescent cells promote tissue NAD+ decline by activating CD38. The ectoenzyme that consumes NAD+ outside cells. That is a substantive advance, because it moves the story from a correlation with age to an identified consumer, and it connects NAD+ decline to cellular senescence, which is independently implicated in ageing.

Research material referenced

NAD+ 500mg, third-party HPLC tested

Buy NAD+ · £49.99

Where the logic gets stretched

From a decline plus a mechanism, it is tempting to conclude that restoring NAD+ will reverse what the decline caused. That does not follow. Falling NAD+ may be a consequence of ageing processes rather than a driver of them, and increasing supply does not necessarily reduce the consumption that caused the fall. The 2021 Nature Reviews Molecular Cell Biology review is careful about this in ways downstream summaries usually are not.

What restoring it has actually shown

Precursor supplementation raises NAD+-related markers in at least some tissues in humans. This part is reasonably supported. What it has not shown is durable change in the clinical outcomes people care about. NADPARK was a phase I trial in Parkinson's disease; Orr's 2024 study in older adults was placebo-controlled and modest in scope. These are early-stage findings.

Why this literature attracts overstatement

A measurable molecule that declines with age, with an identified mechanism and an available intervention, is an unusually clean-looking story. Cleanness invites confidence. The gap between raising a biomarker and changing an outcome is where most of the overstatement lives, and it is the same gap that separates every surrogate endpoint from the thing it stands in for.

What is not claimed here

That NAD+ or its precursors slow ageing, extend life, or affect any condition in any person. The material supplied here is for laboratory research, holds no marketing authorisation, and the trial evidence described concerns precursors administered under clinical supervision.

Frequently asked questions

Does NAD+ really decline with age?

Yes. That observation is reasonably well replicated across tissues and species.

What causes the decline?

Covarrubias 2020 reported that senescent cells drive it by increasing CD38 activity, which consumes NAD+ outside cells.

Does restoring NAD+ reverse ageing effects?

Not established. Precursors raise NAD+-related markers, but durable clinical outcome data does not exist.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More NAD+ articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.